Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.16 USD
Change Today +0.01 / 0.16%
Volume 24.3K
ARGS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

argos therapeutics inc (ARGS) Snapshot

Open
$6.17
Previous Close
$6.15
Day High
$6.20
Day Low
$6.09
52 Week High
09/10/14 - $10.80
52 Week Low
08/14/15 - $4.11
Market Cap
127.4M
Average Volume 10 Days
73.4K
EPS TTM
$-3.44
Shares Outstanding
20.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARGOS THERAPEUTICS INC (ARGS)

Related News

No related news articles were found.

argos therapeutics inc (ARGS) Related Businessweek News

No Related Businessweek News Found

argos therapeutics inc (ARGS) Details

Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its development stage products include AGS-003, which is under Phase III clinical trials for the treatment of metastatic renal cell carcinoma and other cancers; and AGS-004, which is in phase 2 clinical trial for the treatment of Human Immunodeficiency Virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.

113 Employees
Last Reported Date: 03/31/15
Founded in 1997

argos therapeutics inc (ARGS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $543.6K
Chief Operating officer and Vice President of...
Total Annual Compensation: $357.0K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: $382.5K
Compensation as of Fiscal Year 2014.

argos therapeutics inc (ARGS) Key Developments

Argos Therapeutics, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Argos Therapeutics, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2015. For the second quarter, the company’s revenue for the three months ended June 30, 2015 totaled $107,391 compared to $473,163 for the same period in 2014. Operating loss was $18,886,801 against $11,961,793 a year ago. Net loss attributable to common stockholders for the three months ended June 30, 2015 was $19,604,818, or $0.95 per basic and diluted share, compared to a net loss attributable to common stockholders of $11,983,531, or $0.61 per basic and diluted share, for the same period in 2014. For the six months, the company’s revenue for the six months ended June 30, 2015 totaled $286,162 compared to $1,271,951 for the same period in 2014. Operating loss was $35,846,213 against $21,568,676 a year ago. Net loss attributable to common stockholders for the six months ended June 30, 2015 was $37,151,033, or $1.84 per basic and diluted share, compared to a net loss attributable to common stockholders of $22,847,737, or $1.52 per basic and diluted share, for the same period in 2014.

Argos Therapeutics Announces Initiation of Single-Center Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma

Argos Therapeutics Inc. announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma. The study is being conducted at Roswell Park Cancer Institute (RPCI) in Buffalo, New York, and is designed to enroll a maximum of ten patients who will be treated with AGS-003 before nephrectomy in order to assess immune system response and tumor effects. AGS-003 is an autologous dendritic-cell-based immunotherapy designed to induce a memory T-cell response specific to each patient's unique tumor antigens. It is produced using a small sample from a patient's own tumor and dendritic cells derived from a leukapheresis procedure. In an open-label phase 2 study, treatment with AGS-003 plus sunitinib yielded a median overall survival of more than 30 months in newly diagnosed, unfavorable-risk metastatic renal cell carcinoma patients. Argos is evaluating AGS-003 in the pivotal phase 3 ADAPT trial in combination with standard targeted therapy for the treatment of metastatic renal cell carcinoma. The ADAPT trial is fully enrolled; interim data analyses are expected next year, with final data expected in the first part of 2017. The pilot study is in patients with localized renal cell carcinoma, who must be eligible to undergo a partial or radical nephrectomy. Patients will receive five weekly doses of AGS-003 prior to surgery and will remain in the study for approximately six months.

Argos Therapeutics, Inc. to Report Q2, 2015 Results on Aug 12, 2015

Argos Therapeutics, Inc. announced that they will report Q2, 2015 results on Aug 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARGS:US $6.16 USD +0.01

ARGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARGS.
View Industry Companies
 

Industry Analysis

ARGS

Industry Average

Valuation ARGS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARGOS THERAPEUTICS INC, please visit www.argostherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.